CytoMed Therapeutics (GDTC) Current Deferred Revenue (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Current Deferred Revenue for 5 consecutive years, with $138724.3 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 71.27% to $138724.3 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $138724.3 through Dec 2025, up 71.27% year-over-year, with the annual reading at $139819.0 for FY2025, 77.29% up from the prior year.
  • Current Deferred Revenue hit $138724.3 in Q4 2025 for CytoMed Therapeutics, up from $80997.9 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $138724.3 in Q4 2025 to a low of $2524.8 in Q4 2022.
  • Historically, Current Deferred Revenue has averaged $47246.1 across 5 years, with a median of $9942.1 in 2021.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 74.6% in 2022 and later soared 1904.29% in 2024.
  • Year by year, Current Deferred Revenue stood at $9942.1 in 2021, then crashed by 74.6% to $2524.8 in 2022, then skyrocketed by 60.06% to $4041.2 in 2023, then skyrocketed by 1904.29% to $80997.9 in 2024, then soared by 71.27% to $138724.3 in 2025.
  • Business Quant data shows Current Deferred Revenue for GDTC at $138724.3 in Q4 2025, $80997.9 in Q4 2024, and $4041.2 in Q4 2023.